Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023

Rhea-AI Summary

Mirati Therapeutics (NASDAQ: MRTX) will announce first quarter 2023 financial results on May 9, 2023, at 4:30 p.m. ET. The event will include corporate updates and a review of financial results. Investors can listen to the call via a live webcast on Mirati's website or by dialing specific U.S. and international phone numbers.

Mirati is committed to developing therapies for cancer, focusing on unmet needs in areas like lung cancer. The company is advancing several promising therapeutics, including KRAZATI® (adagrasib), which targets genetic drivers of cancer. However, investors are reminded that forward-looking statements in the release carry risks and uncertainties, including those associated with COVID-19 and drug development processes.

Positive

• Upcoming financial results announcement on May 9, 2023.
• Focus on developing breakthrough cancer therapies, addressing high unmet medical needs.

Negative

• Risks and uncertainties related to COVID-19 impacts on business.
• Forward-looking statements highlight potential variations from expected outcomes.

SAN DIEGO, April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on May 9, company executives will provide company updates and review financial results.

Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-394-8218, confirmation code: 8109078. A replay of the call will be available approximately 2 hours after the event has ended at the same website.

About Mirati Therapeutics, Inc.  

Mirati Therapeutics, Inc.is a commercial stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn, and Facebook.

Forward Looking Statements

This press release includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and commercial potential of KRAZATI^® (adagrasib), sitravatinib (TAM receptor inhibitor), MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective KRAS^G12D inhibitor), Mirati's technologies and Mirati's other products in development. Any statement describing Mirati's goals, expectations, intentions or beliefs, financial or other projections, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines.

Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati's annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission and available at the SEC's Internet site (www.sec.gov). These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Mirati Contacts

Investor Relations: ir@mirati.com
Media Relations: media@mirati.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mirati-therapeutics-to-report-first-quarter-2023-financial-results-and-recent-corporate-updates-on-may-9-2023-301807301.html

SOURCE Mirati Therapeutics, Inc.

FAQ

When will Mirati Therapeutics announce its financial results for Q1 2023?

Mirati Therapeutics will announce its financial results for Q1 2023 on May 9, 2023.

What time is the Mirati Therapeutics conference call on May 9, 2023?

The conference call will take place at 4:30 p.m. ET.

How can I listen to the Mirati Therapeutics financial results call?

You can listen to the call via a live webcast on Mirati's website or by dialing specific U.S. and international phone numbers.

What is the focus of Mirati Therapeutics' therapy development?

Mirati Therapeutics focuses on developing breakthrough therapies for cancer, particularly targeting genetic and immunological drivers.

Are there any risks associated with Mirati Therapeutics' forward-looking statements?

Yes, the forward-looking statements are subject to risks and uncertainties, including potential impacts from COVID-19.